| Metric | Q2 2026 | Q2 2025 |
|---|---|---|
| Revenue | 0.1 | 0.0 |
| Net income | -0.5 | -2.5 |
| EPS (diluted, $ a share) | $-0.03 | $-0.98 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +82.1% |
|---|
10-Q filed with the SEC, NASDAQ: VIVS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
VivoSim Labs, INC.: key numbers
- Share price
- $0.1237Close, Nov 16
- Market cap
- $2.51M
- Shares outstanding
- 20.28MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from VivoSim Labs, INC.
All →VivoSim Labs Business Update
VivoSim Labs' subsidiary Organovo entered into a second lease amendment for its principal executive offices in San Diego. The amendment reduces the leased square footage by vacating Suite 202, extends the term for Suite 100 through April 2028, and sets a new monthly base rent of $43,072.85 with a partial rent abatement in early 2027.
- Counterparty
- San Diego Inspire 2, LLC
- Term
- through April 30, 2028
VivoSim Labs Shareholder Meeting
VivoSim Labs held its 2026 Annual Meeting of Stockholders where shareholders elected two Class III directors and ratified the appointment of Rosenberg Rich Baker Berman P.A. as auditors. Stockholders also approved an amendment to the 2022 Equity Incentive Plan to increase the share reserve by 3,165,000 shares and passed an advisory vote on executive compensation.